PMID- 28427847
OWN - NLM
STAT- MEDLINE
DCOM- 20180925
LR  - 20220129
IS  - 1873-2518 (Electronic)
IS  - 0264-410X (Linking)
VI  - 36
IP  - 25
DP  - 2018 Jun 14
TI  - Tetanus vaccines: WHO position paper, February 2017 - Recommendations.
PG  - 3573-3575
LID - S0264-410X(17)30228-1 [pii]
LID - 10.1016/j.vaccine.2017.02.034 [doi]
AB  - This article presents the World Health Organization's (WHO) recommendations on 
      the use of tetanus toxoid (TT) vaccines excerpted from the WHO position paper on 
      tetanus vaccines - February 2017, published in the Weekly Epidemiological Record 
      [1]. This position paper replaces the May 2006 WHO position paper on tetanus 
      vaccines (Tetanus vaccines: WHO position paper, 2006). The position paper 
      summarizes the recent developments in the field of tetanus prevention and 
      provides revised guidance on the optimal timing of recommended tetanus vaccine 
      booster doses. Footnotes to this paper provide a number of core references 
      including references to grading tables that assess the quality of the scientific 
      evidence, and to the evidence-to-recommendation table. In accordance with its 
      mandate to provide guidance to Member States on health policy matters, WHO issues 
      a series of regularly updated position papers on vaccines and combinations of 
      vaccines against diseases that have an international public health impact. These 
      papers are concerned primarily with the use of vaccines in large-scale 
      immunization programmes; they summarize essential background information on 
      diseases and vaccines, and conclude with WHO's current position on the use of 
      vaccines in the global context. Recommendations on the use of TT-containing 
      vaccines (TTCVs) were discussed by SAGE in October 2016; evidence presented at 
      the meeting can be accessed at: 
      http://www.who.int/immunization/sage/meetings/2016/october/presentations_background_docs/en/.
CI  - Copyright (c) 2017 World Health Organization. Published by Elsevier Ltd.. All 
      rights reserved.
CN  - World Health Organization. Electronic address: sageexecsec@who.int
AD  - WHO, Immunization, Vaccines and Biologicals, 20 Ave Appia, CH-1211 Geneva 27, 
      Switzerland.
LA  - eng
GR  - 001/WHO_/World Health Organization/International
PT  - Journal Article
DEP - 20170418
PL  - Netherlands
TA  - Vaccine
JT  - Vaccine
JID - 8406899
RN  - 0 (Tetanus Toxoid)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Female
MH  - *Health Policy
MH  - Humans
MH  - Immunization Programs
MH  - Immunization Schedule
MH  - Immunization, Secondary/methods
MH  - Infant
MH  - *Practice Guidelines as Topic
MH  - Pregnancy
MH  - Tetanus/immunology/*prevention & control/virology
MH  - Tetanus Toxoid/*administration & dosage
MH  - *Vaccination
MH  - World Health Organization
OTO - NOTNLM
OT  - Maternal and neonatal tetanus elimination (MNTE)
OT  - Tetanus vaccines
OT  - Tetanus-toxoid-containing vaccines (TTCV)
OT  - Vaccine position paper
OT  - WHO position paper
EDAT- 2017/04/22 06:00
MHDA- 2018/09/27 06:00
CRDT- 2017/04/22 06:00
PHST- 2017/02/14 00:00 [received]
PHST- 2017/02/15 00:00 [accepted]
PHST- 2017/04/22 06:00 [pubmed]
PHST- 2018/09/27 06:00 [medline]
PHST- 2017/04/22 06:00 [entrez]
AID - S0264-410X(17)30228-1 [pii]
AID - 10.1016/j.vaccine.2017.02.034 [doi]
PST - ppublish
SO  - Vaccine. 2018 Jun 14;36(25):3573-3575. doi: 10.1016/j.vaccine.2017.02.034. Epub 
      2017 Apr 18.